drugset / Trial / NCT06571591

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

NCT06571591

Phase 3 Completed 606 enrolled Celltrion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.

Timeline

Start
2024-08-27
Primary completion
2026-04-16
Completion
2026-05-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule Oral
Comparator Empagliflozin Small molecule Oral
Comparator Metformin Small molecule Oral